Lipella Pharmaceuticals Inc.

NasdaqCM LIPO

Lipella Pharmaceuticals Inc. Price to Earnings Ratio (P/E) on January 14, 2025

Lipella Pharmaceuticals Inc. Price to Earnings Ratio (P/E) is NA on January 14, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Lipella Pharmaceuticals Inc. 52-week high Price to Earnings Ratio (P/E) is 0.13 on January 17, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Lipella Pharmaceuticals Inc. 52-week low Price to Earnings Ratio (P/E) is -0.13 on May 15, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Lipella Pharmaceuticals Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.01.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: LIPO

Lipella Pharmaceuticals Inc.

CEO	Dr. Jonathan Kaufman M.B.A., Ph.D.
IPO Date	Dec. 19, 2022
Location	United States
Headquarters	7800 Susquehanna St.
Employees	5
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Key trends

Past 5 years